mTOR Inhibition for Cancer Therapy: Past, Present and Future
(Sprache: Englisch)
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as...
Jetzt vorbestellen
versandkostenfrei
Buch (Gebunden)
109.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „mTOR Inhibition for Cancer Therapy: Past, Present and Future “
Klappentext zu „mTOR Inhibition for Cancer Therapy: Past, Present and Future “
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
Inhaltsverzeichnis zu „mTOR Inhibition for Cancer Therapy: Past, Present and Future “
- Forward- Past
- mTOR inhibitors: a little bit of history
- Present
- The mTOR pathway
- The evolving role of mTOR inhibitors in renal cell carcinoma
- The role of mTOR inhibitors in breast cancer
- The role of mTOR inhibitors in neuroendocrine tumors
- New indications of mTOR inhibitors in rare tumors
- The role of mTOR inhibitors in the treatment of hematological malignancies
- The clinical pharmacology and toxicity profile of rapalogs
- Resistance to mTOR inhibitors
- Rational combinations of mTOR inhibitors as anticancer strategies
- Future
- Predictive biomarkers of response to mTOR inhibitors
- The potential future indication of rapamycin analogs for the treatment of other solid tumors
- mTOR inhibition beyond rapalogs
- mTOR, aging and cancer: the missing link?
- New study design for mTOR inhibitors and other biological agents
- Future directions for the development of mTOR inhibitors
Autoren-Porträt
Monica Mita and Alain Mita are Associate Professors of Medicine and Co-Directors of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer institute, Cedars-Sinai Medical Center in Los Angeles, CA. Eric Rowinsky is Chief Medical Officer, Head of Research and Development, and Executive Vice President at Stemline Therapeutics, Inc. He is also an Adjunct Professor of Medicine at New York University School of Medicine and a cancer drug development consultant at Oncodrugs.
Bibliographische Angaben
- 2015, 1st ed. 2016, 300 Seiten, Maße: 15,9 x 24,1 cm, Gebunden, Englisch
- Herausgegeben: Monica Mita, Alain Mita, Eric K. Rowinsky
- Verlag: Springer, Berlin
- ISBN-10: 2817804910
- ISBN-13: 9782817804910
- Erscheinungsdatum: 30.11.2015
Sprache:
Englisch
Kommentar zu "mTOR Inhibition for Cancer Therapy: Past, Present and Future"
Schreiben Sie einen Kommentar zu "mTOR Inhibition for Cancer Therapy: Past, Present and Future".
Kommentar verfassen